252 related articles for article (PubMed ID: 21911059)
1. Substitution at carbon 2 of 19-nor-1α,25-dihydroxyvitamin D3 with 3-hydroxypropyl group generates an analogue with enhanced chemotherapeutic potency in PC-3 prostate cancer cells.
Iglesias-Gato D; Zheng S; Flanagan JN; Jiang L; Kittaka A; Sakaki T; Yamamoto K; Itoh T; Lebrasseur NK; Norstedt G; Chen TC
J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):269-75. PubMed ID: 21911059
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer.
Flanagan JN; Zheng S; Chiang KC; Kittaka A; Sakaki T; Nakabayashi S; Zhao X; Spanjaard RA; Persons KS; Mathieu JS; Holick MF; Chen TC
Anticancer Res; 2009 Sep; 29(9):3547-53. PubMed ID: 19667147
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of C-2-substituted 19-nor-1alpha,25-dihydroxyvitamin D3 analogs as therapeutic agents for prostate cancer.
Chen TC; Persons KS; Zheng S; Mathieu J; Holick MF; Lee YF; Bao B; Arai MA; Kittaka A
J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):717-20. PubMed ID: 17207993
[TBL] [Abstract][Full Text] [Related]
4. MART-10, a less calcemic vitamin D analog, is more potent than 1α,25-dihydroxyvitamin D3 in inhibiting the metastatic potential of MCF-7 breast cancer cells in vitro.
Chiang KC; Chen SC; Yeh CN; Pang JH; Shen SC; Hsu JT; Liu YY; Chen LW; Kuo SF; Takano M; Kittaka A; Sun CC; Juang HH; Chen TC
J Steroid Biochem Mol Biol; 2014 Jan; 139():54-60. PubMed ID: 24125734
[TBL] [Abstract][Full Text] [Related]
5. Human cytochrome P450-dependent differential metabolism among three 2α-substituted-1α,25-dihydroxyvitamin D(3) analogs.
Yasuda K; Ikushiro S; Kamakura M; Takano M; Saito N; Kittaka A; Chen TC; Ohta M; Sakaki T
J Steroid Biochem Mol Biol; 2013 Jan; 133():84-92. PubMed ID: 22982757
[TBL] [Abstract][Full Text] [Related]
6. 19-Nor-2α-(3-hydroxypropyl)-1α,25-dihydroxyvitamin D3 (MART-10) is a potent cell growth regulator with enhanced chemotherapeutic potency in liver cancer cells.
Chiang KC; Yeh CN; Chen HY; Lee JM; Juang HH; Chen MF; Takano M; Kittaka A; Chen TC
Steroids; 2011 Dec; 76(13):1513-9. PubMed ID: 21888924
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of the anti-proliferative action of 25-hydroxy-19-nor-vitamin D(3) in human prostate cells.
Munetsuna E; Nakabayashi S; Kawanami R; Yasuda K; Ohta M; Arai MA; Kittaka A; Chen TC; Kamakura M; Ikushiro S; Sakaki T
J Mol Endocrinol; 2011 Oct; 47(2):209-18. PubMed ID: 21693624
[TBL] [Abstract][Full Text] [Related]
8. Anti-proliferative activity of 25-hydroxyvitamin D3 in human prostate cells.
Munetsuna E; Kawanami R; Nishikawa M; Ikeda S; Nakabayashi S; Yasuda K; Ohta M; Kamakura M; Ikushiro S; Sakaki T
Mol Cell Endocrinol; 2014 Feb; 382(2):960-70. PubMed ID: 24291609
[TBL] [Abstract][Full Text] [Related]
9. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
10. Potent antiproliferative effects of 25-hydroxy-16-ene-23-yne-vitamin D₃ that resists the catalytic activity of both CYP27B1 and CYP24A1.
Rhieu SY; Annalora AJ; LaPorta E; Welsh J; Itoh T; Yamamoto K; Sakaki T; Chen TC; Uskokovic MR; Reddy GS
J Cell Biochem; 2014 Aug; 115(8):1392-402. PubMed ID: 24535953
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
Swamy N; Chen TC; Peleg S; Dhawan P; Christakos S; Stewart LV; Weigel NL; Mehta RG; Holick MF; Ray R
Clin Cancer Res; 2004 Dec; 10(23):8018-27. PubMed ID: 15585637
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.
Chen TC; Holick MF; Lokeshwar BL; Burnstein KL; Schwartz GG
Recent Results Cancer Res; 2003; 164():273-88. PubMed ID: 12899529
[TBL] [Abstract][Full Text] [Related]
13. Kinetic studies of 25-hydroxy-19-nor-vitamin D3 and 1 alpha,25-dihydroxy-19-nor-vitamin D3 hydroxylation by CYP27B1 and CYP24A1.
Urushino N; Nakabayashi S; Arai MA; Kittaka A; Chen TC; Yamamoto K; Hayashi K; Kato S; Ohta M; Kamakura M; Ikushiro S; Sakaki T
Drug Metab Dispos; 2007 Sep; 35(9):1482-8. PubMed ID: 17553915
[TBL] [Abstract][Full Text] [Related]
14. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
15. MART-10, a novel vitamin D analog, inhibits head and neck squamous carcinoma cells growth through cell cycle arrest at G0/G1 with upregulation of p21 and p27 and downregulation of telomerase.
Chiang KC; Yeh CN; Hsu JT; Chen LW; Kuo SF; Sun CC; Huang CC; Pang JH; Flanagan JN; Takano M; Kittaka A; Juang HH; Yang SW; Chen TC
J Steroid Biochem Mol Biol; 2013 Nov; 138():427-34. PubMed ID: 24044969
[TBL] [Abstract][Full Text] [Related]
16. Temporal changes in tissue 1α,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice.
Chow EC; Quach HP; Vieth R; Pang KS
Am J Physiol Endocrinol Metab; 2013 May; 304(9):E977-89. PubMed ID: 23482451
[TBL] [Abstract][Full Text] [Related]
17. Novel metabolism of 1 alpha,25-dihydroxyvitamin D3 with C24-C25 bond cleavage catalyzed by human CYP24A1.
Sawada N; Kusudo T; Sakaki T; Hatakeyama S; Hanada M; Abe D; Kamao M; Okano T; Ohta M; Inouye K
Biochemistry; 2004 Apr; 43(15):4530-7. PubMed ID: 15078099
[TBL] [Abstract][Full Text] [Related]
18. MART-10, the vitamin D analog, is a potent drug to inhibit anaplastic thyroid cancer cell metastatic potential.
Chiang KC; Kuo SF; Chen CH; Ng S; Lin SF; Yeh CN; Chen LW; Takano M; Chen TC; Juang HH; Kittaka A; Lin JD; Pang JH
Cancer Lett; 2015 Dec; 369(1):76-85. PubMed ID: 26282787
[TBL] [Abstract][Full Text] [Related]
19. 19-Norvitamin D analogs for breast cancer therapy.
Matsumoto Y; Kittaka A; Chen TC
Can J Physiol Pharmacol; 2015 May; 93(5):333-48. PubMed ID: 25918960
[TBL] [Abstract][Full Text] [Related]
20. CYP24A1 as a potential target for cancer therapy.
Sakaki T; Yasuda K; Kittaka A; Yamamoto K; Chen TC
Anticancer Agents Med Chem; 2014 Jan; 14(1):97-108. PubMed ID: 23869781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
